Newswire

Newswire

Dexioprotocol to be listed on second major exchange

The listing on MEXC Global represents Dexioprotocol’s second top tier exchange listing and third centralized exchange listing. DEXI is already listed on Lbank Exchange, P2PB2B, and PancakeSwap. Prior to trading opening, Dexioprotocol is participating in the MEXC Kickstarter event, where…

Vaisala Oyj tilinpäätöstiedote tammi–joulukuu 2023

Vaisala Oyj                Tilinpäätöstiedote                                18.2.2023 klo 9.00 Vaisala Oyj tilinpäätöstiedote tammi–joulukuu 2021Kasvun ja erinomaisen tuloksen vuosi päättyi neljännen neljänneksen liikevaihdon vahvaan kasvuun Neljäs neljännes 2021 lyhyesti Saadut tilaukset 119,0 (111,9) miljoonaa euroa, kasvua 6 % Tilauskanta kauden lopussa 160,0 (137,8) miljoonaa euroa, kasvua…

Vaisala Corporation Financial Statement Release January–December 2023

Vaisala Corporation        Financial Statement Release                February 18, 2023, at 9.00 a.m. (EET) Vaisala Corporation Financial Statement Release January–December 2021Year of growth and excellent performance ended with strong net sales growth in Q4 Fourth quarter 2021 highlights Orders received EUR 119.0 (111.9) million,…

Agricultural Irrigation Machinery Market Size in the US to Grow by USD 881.82 Billion | By Type (sprinkler irrigation, drip irrigation, pivot irrigation, and others) and Application (grains and cereals, pulses and oilseeds, fruits and vegetables, and others) | Growth, Trends, and Forecasts (2023 – 2026)

Download FREE Sample: for more additional information about the key segments of the market Segmentation Analysis & Forecasts The agricultural irrigation machinery market share growth in the US by the sprinkler irrigation segment will be significant during the forecast period. The increase in preference for new…

Bioasis Announces $200,000 Non-Brokered Private Placement

NEW HAVEN, Conn., Feb. 17, 2023 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment…